Betty Hamilton

Feb 23, 2024 | onclive.com | Betty Hamilton

Betty Hamilton, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses an investigation into the health-related quality of life (HRQOL) differences between post-transplant treatment with gilteritinib (Xospata) vs placebo in patients with FLT3-ITD–positive acute myeloid leukemia (AML).

Feb 23, 2024 | newsbreak.com | Betty Hamilton

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy

Feb 23, 2024 | targetedonc.com | Betty Hamilton

Betty K.

Sep 12, 2023 | nature.com | Wei Wei |Faiz Anwer |Robert Dean |Betty Hamilton

AbstractRecently there has been a growing interest in evaluating body composition as a marker for prognosis in cancer patients. The association of body composition parameters and outcomes has not been deeply investigated in patients with autologous hematopoietic stem cell transplantation (HSCT) recipients with non-Hodgkin lymphoma (NHL). We conducted a retrospective cohort study of 264 NHL patients who received autologous HSCT.

Feb 11, 2023 | nature.com | Betty Hamilton |Aaron Gerds |Faiz Anwer |Robert Dean

This is a preview of subscription content, access via your institution Access options Subscribe to JournalGet full journal access for 1 year$119.00only $9.92 per issueAll prices are NET prices. VAT will be added later in the checkout. Tax calculation will be finalised during checkout. Buy articleGet time limited or full article access on ReadCube. $32.00All prices are NET prices.